Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSMO: Switch from omalizumab to mepolizumab in severe eosinophilic asthma
2015-003697-32Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in eosinophilic asthma (EA) and asthma, sponsored by GSK. Primary endpoint: Asthma control (ACQ-5). Started Nov 2015; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)asthma
Beyond the preview
Go deeper on 2015-003697-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003697-32.